APPENDICURE

RESEARCH SPOTLIGHT  ·  TREATMENT ACCESS

When standard treatment runs out, a handful of legal pathways may open the door to investigational therapies. Here is what they actually are, how they work, and what to ask for.

One of the hardest realities of a rare cancer is that promising therapies often exist for years before patients can get to them. Families hear some version of the same three sentences. The drug is still in trials. It is approved for another cancer, but not appendix cancer. The science looks promising, but access is limited.

There are pathways that sit outside those three sentences. In the United States and many other countries, patients with serious illness who have run out of standard options can sometimes request access to investigational drugs through programs with names like Right to Try, Expanded Access, Compassionate Use, Named Patient access, and Early Access. None of these is a guaranteed door. All of them are doors worth knowing about.

Right to Try in the United States

The federal Right to Try Act became law in 2018. It allows eligible patients with life-threatening illness to request access to investigational drugs that the FDA has not yet approved. The law was written for people who have exhausted approved treatment, cannot enroll in a clinical trial, and want to try a therapy that is still in development.

The law does not require the FDA to review the request. It also does not require the drug company to say yes. Manufacturers can, and often do, decline. Right to Try opens a path. It does not promise delivery.

Who qualifies

• A life-threatening diagnosis
• Standard treatment options have been exhausted
• The patient is not eligible for an open clinical trial
• A physician is willing to make the request
• The drug has completed at least a Phase I human trial

The Phase I trial does not have to have been in appendix cancer. That single point matters more than almost anything else in this article.

A pancreatic cancer drug, a colorectal drug, an immunotherapy, a cell therapy, or a biomarker-driven therapy can all potentially qualify if a physician and a manufacturer believe the biology might apply to an appendiceal tumor. For a disease that often borrows its treatment playbook from other cancers, this is the most useful sentence in the federal statute.

Expanded Access and Compassionate Use

In practice, most oncology teams reach for Expanded Access before they reach for Right to Try. Expanded Access, often called Compassionate Use, is the FDA’s longstanding pathway for patients with serious illness to seek investigational therapies outside a clinical trial.

The structure is different from Right to Try. The FDA reviews each request. An institutional review board is usually involved. Documentation is more extensive. The trade-off for that overhead is real, established infrastructure. The FDA approves the large majority of Expanded Access requests that reach the agency.

Right to Try vs. Expanded Access at a glance

	Right to Try	Expanded Access
FDA reviews the request	No	Yes
Requires completed Phase I	Yes	Usually yes
Physician involvement	Required	Required
Manufacturer must agree	Yes	Yes
Patient typically unable to enroll in a trial	Yes	Yes
Regulatory oversight	Lower	Higher
More commonly used in practice	Less common	More common

Why this matters for appendix cancer

Appendix cancer sits in a difficult place for trial access. The patient population is small. Disease-specific trials are scarce. Treatment decisions often borrow from colorectal, pancreatic, ovarian, and neuroendocrine research. The result is that many appendix cancer patients run out of standard options before they run out of biological reasons to try something else.

That is exactly the situation these pathways were written for. Patients with appendiceal tumors may particularly benefit from approaches that do not depend on appendix-specific trials, including:

• Molecular profiling and genomic testing to identify targetable alterations
• ctDNA testing for recurrence monitoring and treatment guidance
• Basket trials that enroll based on biomarker rather than tumor location
• Tumor-agnostic therapies approved for genomic features rather than primary site
• Expanded Access pathways for drugs that have shown signal in adjacent cancers

The biggest misunderstanding Qualifying for a program is not the same as receiving the drug. Even when a patient is eligible, the manufacturer can decline. Drug supply can be limited. The patient may be considered too medically fragile. The company may worry about complications affecting their trial data.This is one of the reasons patient advocacy groups continue to push for more transparent access policies, particularly for rare cancers like appendiceal disease.

Questions to ask your oncology team

Before reaching for an early-access program, walk through these with your medical team. The answers shape which pathway, if any, is the right one.

• Is there an appropriate clinical trial we have not considered? Trials are the preferred route when one exists, and basket and tumor-agnostic trials may apply even when no appendix-specific trial does.
• Is the drug already approved for another cancer? If so, off-label prescribing may be possible without going through Right to Try or Expanded Access at all.
• Does my tumor carry a biomarker that opens a tumor-agnostic option? Examples include MSI-H, TMB-high, NTRK fusions, KRAS mutations, and HER2 amplification.
• Does the manufacturer have a published Expanded Access policy? Some companies post their criteria publicly, which speeds up the assessment.
• Am I medically eligible right now? Performance status, organ function, and prior treatment all factor into both Right to Try and Expanded Access.
• Are there international trial or access options worth exploring? For appendix cancer patients, the relevant trial sometimes sits in a different country.

Early-access programs in other countries

Many of the countries represented in the Appendicure community have their own version of these pathways. The names differ. The shape is similar. A patient with serious illness, a physician willing to advocate, and a manufacturer willing to supply the drug can sometimes access an investigational therapy before formal approval.

Below is the short version. For the full list of regulatory agencies, application pathways, and links by country, we keep that information on a dedicated Appendicure resource page so it can be updated as programs evolve.

Country	Pathway
United States	Right to Try, Expanded Access (Compassionate Use)
United Kingdom	Early Access to Medicines Scheme (EAMS), Named Patient access
Canada	Special Access Program (SAP)
Australia	Special Access Scheme (SAS), Authorised Prescriber pathway
Germany	Compassionate Use and Named Patient Programs under EU framework
New Zealand	Medsafe-named patient prescribing
Ireland	Compassionate access and named-patient mechanisms
India	Compassionate use and accelerated approval pathways
Sweden	EU-coordinated compassionate use and named patient access
Israel	Ministry of Health compassionate use and early access

For the full country guide Visit Early Access Programs Per Country for current agency links, application instructions, and contact pathways for each country. We update that page as programs change. These are the countries represented at Appendicure today. As more people from other countries join I’ll add them here.

What these programs cannot promise

Investigational access is not a backup plan in the way the name suggests. The programs exist. The drugs exist. The path between them runs through several gates, and any gate can close.

Patients and families should weigh the practical and emotional cost honestly. Travel may be required. Insurance may not cover the drug or the supportive care around it. Out-of-pocket costs can be substantial. Side effects and safety profile are, by definition, less well understood than they would be for an approved therapy. And the most difficult truth: access does not guarantee benefit. Some patients respond dramatically. Others do not.

For appendix cancer specifically, where the evidence base is thin and treatment decisions are often individualized, having an honest conversation about likelihood of benefit, not just likelihood of access, is essential before going down this road.

For appendix cancer patients facing limited treatment options, investigational-access programs may open another path. Access depends on physician support, manufacturer willingness, eligibility, and a careful risk-and-benefit conversation.

Glossary

Compassionate Use	Access to investigational therapies outside clinical trials for patients with serious illness.
Expanded Access	The FDA-regulated U.S. pathway for compassionate use.
Right to Try	A U.S. law allowing eligible patients to seek certain investigational therapies without direct FDA review.
Named Patient Program	A physician-requested pathway allowing access for an individual patient, common outside the United States.
Tumor-Agnostic Therapy	A treatment approved based on biomarkers rather than the cancer’s primary location.
Basket Trial	A clinical trial that enrolls patients with different cancer types but shared molecular features.
Phase I Trial	An early-stage human trial primarily evaluating safety and dosing.

Sources

• U.S. FDA, Right to Try guidance
• U.S. FDA, Expanded Access guidance
• MHRA, Early Access to Medicines Scheme (United Kingdom)
• Health Canada, Special Access Program
• Therapeutic Goods Administration, Special Access Scheme (Australia)

Share with your communityMany appendix cancer patients and caregivers have never heard the words Expanded Access, Compassionate Use, or Right to Try. Sharing this article helps families ask better questions and advocate more clearly for themselves. Tag @appendicure and use #AppendixCancer when you do.

Medical disclaimer. This article is for educational purposes only and does not constitute medical or legal advice. Eligibility for investigational-access programs varies by country, institution, manufacturer policy, and individual medical circumstances. Patients should discuss all treatment decisions with their oncology team and qualified healthcare professionals.